Oprozomib

Drug Profile

Oprozomib

Alternative Names: ONO-7058; ONX-012; ONX-0912; OPZ; PR-047

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Onyx Pharmaceuticals
  • Class Amides; Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules; Thiazoles
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Phase I/II Haematological malignancies; Multiple myeloma
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy, Recurrent, Second-line therapy or greater) in USA (PO, Tablet)
  • 01 Jan 2017 Amgen initiates enrolment in the INTREPID-1 trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (NCT02939183)
  • 03 Dec 2016 Final adverse events and efficacy data from a phase Ib/II trial in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top